Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 4/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7267845 | 0.93 | BRD4 (0.33) | PTGS2BRD4CREBBPKDM4ERAD52 | |
| SCHEMBL14007744 | 0.79 | MAPT (0.42) | GAAKDM4E | |
| SCHEMBL7266857 | 0.77 | CYP19A1 (0.32) | PTGS2 | |
| SCHEMBL9836843 | 0.76 | PDE2A (0.33) | — | |
| SCHEMBL9838859 | 0.76 | KDM4E (0.42) | KDM4E | |
| SCHEMBL6449692 | 0.75 | LMNA (0.31) | — | |
| SCHEMBL11154284 | 0.75 | SLC6A4 (0.30) | — | |
| SCHEMBL7262493 | 0.75 | ALDH1A1 (0.42) | PTGS2KDM4E | |
| SCHEMBL7272939 | 0.75 | — | — | |
| SCHEMBL14819 | 0.72 | CTNNB1 (0.41) | KDM4ERAD52ATMMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838319-B1 | PDE5 INHIBITOR COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | UNIV JOHNS HOPKINS (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170224691-A1 | PDE INHIBITORS IN IMMUNOTHERAPY | THE JOHNS HOPKINS UNIVERSITY | 2017-08-10 | — | — | US | disclosed |
| US-20170224691-A1 | PDE INHIBITORS IN IMMUNOTHERAPY | THE JOHNS HOPKINS UNIVERSITY | 2017-08-10 | — | — | US | disclosed |
| US-9468643-B2 | PDE5 inhibitor compositions and methods for immunotherapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-18 | — | — | US | disclosed |
| US-9468643-B2 | PDE5 inhibitor compositions and methods for immunotherapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140255433-A1 | PDE5 INHIBITOR COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140255433-A1 | PDE5 INHIBITOR COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130123264-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISORDERS AND INTESTINAL CANCERS | Georgia Health Sciences University | 2013-05-16 | — | — | US | disclosed |
| US-20130123264-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISORDERS AND INTESTINAL CANCERS | Georgia Health Sciences University | 2013-05-16 | — | — | US | disclosed |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| US-5936102-A | CYCLOCONDENSING O-(2-BROMOTETRAFLUOROETHOXY)PHENOL IN THE PRESENCE OF ACID BINDER | BAYER AKTIENGESELLSCHAFT (DE) | 1999-08-10 | — | — | US | disclosed |
| EP-0893444-A1 | Process for reparing 2,2,3,3-tetrafluoro-1,4-benzodioxanes, new o-(2-bromo-1,1,2,2,-tetrafluoroethoxy)-phenols and new2-bromo-1,1,2,2-tetrafuoroethoxy-phenylethers | BAYER AG (DE) | 1999-01-27 | — | — | EP | disclosed |
| US-5344944-A | Cardiovascular insufficiency, increasing the contractive force of the heart | BAYER AKTIENGESELLSCHAFT (DE) | 1994-09-06 | — | — | US | disclosed |
| EP-0291799-B1 | DIOXYALKYLENEARYL-DIHYDROPYRIDINES AND THEIR INTERMEDIARY COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1993-06-16 | — | — | EP | disclosed |
| US-4886816-A | CARDIOTONIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-12-12 | — | — | US | disclosed |
| EP-0291799-A2 | Dioxyalkylenearyl-dihydropyridines and their intermediary compounds, process for their preparation and their use | BAYER AG (DE) | 1988-11-23 | — | — | EP | disclosed |
| US-4438275-A | 2,2-DIFLUORO-BENZODIOXOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-20 | — | — | US | disclosed |
| US-4405639-A | INSECTICIDES; PESTICIDES; MITICIDES; NEMATOCIDES; PARACITICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-09-20 | — | — | US | disclosed |
| US-4348323-A | FLUORINE-CONTAINING BENZODIOXINE INSECTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-07 | — | — | US | disclosed |
| US-4284643-A | Combating arthropods with novel fluorine-containing phenylacetic acid esters | BAYER AKTIENGESELLSCHAFT (DE) | 1981-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123264-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISORDERS AND INTESTINAL CANCERS | PRKG2, PDE5A, PRKG1 | PTGS2 93/4885BRD4 3254/4885CREBBP 2232/4885 |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE2A | PTGS2 249/4885BRD4 2206/4885CREBBP 978/4885 |
| US-20140255433-A1 | PDE5 INHIBITOR COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | PDE5A, PDE3A, PDE2A | PTGS2 855/4885BRD4 1002/4885CREBBP 1771/4885 |
| US-20170224691-A1 | PDE INHIBITORS IN IMMUNOTHERAPY | PDE5A, PDE2A, PDE3A | PTGS2 578/4885BRD4 591/4885CREBBP 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.